Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Has Consensus Target Price of $31.29 According to Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given an average recommendation of “Moderate Buy” by the sixteen brokerages that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $31.29.

Several research analysts have issued reports on the company. HC Wainwright cut their price objective on Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. Raymond James Financial reissued a “strong-buy” rating and set a $37.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 8th. Robert W. Baird decreased their price objective on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $17.00 to $10.00 in a research report on Wednesday, September 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 30th.

Dyne Therapeutics Trading Up 4.1%

NASDAQ DYN opened at $18.07 on Thursday. The stock has a market capitalization of $3.37 billion, a P/E ratio of -4.98 and a beta of 1.22. Dyne Therapeutics has a 52-week low of $14.00 and a 52-week high of $27.31. The firm has a 50-day moving average price of $17.70 and a 200 day moving average price of $19.33. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.15). During the same quarter in the prior year, the firm earned ($0.76) earnings per share. Equities research analysts expect that Dyne Therapeutics will post -3.69 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares of the company’s stock, valued at $10,723,650. The trade was a 83.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas Kerr sold 3,745 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75. Following the completion of the sale, the insider directly owned 163,854 shares in the company, valued at approximately $3,989,844.90. The trade was a 2.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 2,598,706 shares of company stock valued at $65,432,671. Company insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Dyne Therapeutics during the second quarter worth approximately $275,500,000. Jupiter Topco LLC purchased a new stake in shares of Dyne Therapeutics in the second quarter valued at $266,634,000. Bank of America Corp DE purchased a new stake in Dyne Therapeutics in the 2nd quarter valued at about $49,604,000. Palo Alto Investors LP acquired a new position in Dyne Therapeutics during the second quarter worth approximately $36,591,441. Finally, Perceptive Advisors LLC increased its holdings in shares of Dyne Therapeutics by 34.2% during the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock worth $84,646,000 after buying an additional 1,189,895 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: The FDA is conducting a priority review of Dyne’s biologics license application for z-rostudirsen, its exon 51 Duchenne muscular dystrophy (DMD) candidate. The FDA’s target action date is January 21, 2027, providing a defined near-term regulatory catalyst. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Management said its cash runway extends into the second quarter of 2028, providing funding visibility for ongoing development. The company also reported progress in its DMD and DM1 programs ahead of planned 2027 milestones. Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
• Neutral Sentiment: A valuation commentary raised the possibility that DYN is undervalued, citing its pipeline and the FDA priority review, but this is an opinion rather than a new company development. Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
• Negative Sentiment: Third-quarter EPS was a loss of $1.06, wider than analysts’ expected $0.91 loss and the $0.76 loss a year earlier. Reports attributed the increased loss to higher research and development spending, highlighting rising development costs. Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.